General
Preferred name
TRIMETHOBENZAMIDE
Synonyms
TRIMETHOBENZAMIDE HYDROCHLORIDE ()
Trimethobenzamide D6 ()
Ro 2-9578 ()
Tribenzagan Hydrochloride ()
Trimethobenzamide (hydrochloride) ()
NSC-37882 ()
Trimethobenzamide HCl ()
Trimethobenzamide hydrochloride preservative free ()
Tigan ()
Trimetobenzamida ()
Ametik damla ()
P&D ID
PD009863
CAS
554-92-7
138-56-7
Tags
available
drug
Approved by
FDA
First approval
1974
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
post operative nausea and vomiting
allergic disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Trimethobenzamide hydrochloride is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
DESCRIPTION
Trimethobenzamide hydrochloride is the hydrochloride salt form of trimethobenzamide, which is a benzamide derivative with antiemetic property. It is an orally available, antiemetic agent used in the therapy of nausea and vomiting and gastrointestinal, viral and other illnesses. It is generally considered the most potent antiemetic that does not have effects on the serotonergic, dopaminergic, or histaminergic systems. It inhibits the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center, thereby suppressing nausea and vomiting. It is also used in the treatment of Parkinson's disease. It has been withdrawn from the market.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Trimethobenzamide hydrochloride (Ro 2-9578) is a blocker of the D2 receptor. Trimethobenzamide is an antiemetic used to prevent nausea and vomiting.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. It is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
54
Molecular Weight
388.2
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
10
Ring Count
2
Aromatic Ring Count
2
cLogP
2.58
TPSA
69.26
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.67
QED
0.67
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Unknown molecular target
Dopamine Receptor
Histamine Receptor antagonist
Target
D2
dopamine
Influenza Virus
DRD2
Indication
vomiting, nausea, gastroenteritis
Pathway
Anti-infection
GPCR/G protein
Neuronal Signaling
Microbiology/virology
Neuroscience
Solubility
Soluble in DMSO (Slightly), Methanol (Slightly), Water (Slightly)
Source data
